Role of progestogen in hormone therapy for postmenopausal women: Position statement of the North American Menopause Society

Menopause

Volumn 10, Issue 2, 2003, Pages 113-132

[No Author Info available]

Author keywords

Estrogen; Estrogen plus progestogen; Hormone therapy; Menopause; Progesterone; Progestin; Progestogen

Indexed keywords

17BETA ESTRADIOL PLUS NORGESTIMATE; ALTI MPA; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; FEMHRT; GEN MEDROXY; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTIMATE; NORGESTREL; NOVO MEDRONE; ORTHO PREFEST; PREMPLUS; PROGESTERONE; UNCLASSIFIED DRUG;

AMENORRHEA; CARDIOVASCULAR RISK; CORRELATION ANALYSIS; DRUG EFFECT; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; EVIDENCE BASED MEDICINE; HORMONAL THERAPY; HUMAN; INTERNATIONAL COOPERATION; MAMMOGRAPHY; MEDICAL LITERATURE; MEDICAL SOCIETY; MENOPAUSE; MENOPAUSE RELATED DISORDER; MORTALITY; POSTMENOPAUSE; REVIEW; RISK FACTOR; SECONDARY PREVENTION; UTERUS BLEEDING; ARTICLE; ESTROGEN THERAPY; FEMALE; PRACTICE GUIDELINE; WOMEN'S HEALTH;

ENDOMETRIAL HYPERPLASIA; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; POSTMENOPAUSE; PROGESTERONE; WOMEN'S HEALTH;

EID: 0038798005     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042192-200310020-00003     Document Type: Review

References (173)

1. Boggs P, Utian W. The North American Menopause Society develops consensus opinions [editorial]. Menopause 1998;5:67-68.
2. Guyatt GH, Sackett DL, Sinclair JC, et al, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature. IX. A method for grading health care recommendations. JAMA 1995;274:1800-1805.
3. Feder G. Guidelines for clinical guidelines. BMJ 1998;317:427-428.
4. Scottish Intercollegiate Guidelines Network. SIGN Guidelines: An Introduction to SIGN Methodology for the Development of Evidence-Based Clinical Guidelines. Available at: http://www.sign.ac.uk/. Accessed July 27, 2001.
5. Guiochon-Mantel A. Structure of the progesterone receptor and mode of action of progesterone. In: Sitruk-Ware R, Mishell DR, Jr, eds. Progestins and Antiprogestins in Clinical Practice. New York, NY: Marcel Dekker, 2000:1-13.
6. Whitehead MI, Townsend PT, Pryse-Davies J, Ryder TA, King RJ. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 1981;305:1599-1605.
7. King RJ, Townsend PT, Whitehead MI. The role of estradiol dehydrogenase in mediating progestin effects on endometrium from postmenopausal women receiving estrogens and progestins. J Steroid Biochem 1981;14:235-238.
8. Dorflinger LJ. Relative potency of progestins used in oral contraceptives. Contraception 1985;31:557-570.
9. King RJ, Whitehead MI. Assessment of the potency of orally administered progestins in women. Fertil Steril 1986;46:1062-1066.
10. Sitruk-Ware R. Progestins in hormone replacement therapy and prevention of endometrial disease. In: Sitruk-Ware R, Mishell DR, Jr, eds. Progestins and Antiprogestins in Clinical Practice. New York, NY: Marcel Dekker, 2000:269-277.
11. Archer DF. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause 2001;8:245-251.
12. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a metaanalysis. Obstet Gynecol 1995;85:304-313.
13. Persson I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989;298:147-151.
14. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293:1164-1167.
15. Weiderpass E, Adami H-O, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131-1137.
16. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975;293: 1167-1170.
17. Genant HK, Lucas J, Weiss S, et al, for the Estratab/Osteoporosis Study Group. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Arch Intern Med 1997;157:2609-2615.
18. Kurman RJ, Felix JC, Archer DF, Nanavati N, Arce J, Moyer DL. Norethindrone acetate and estradiol-induced endometrial hyperplasia. Obstet Gynecol 2000;96:373-379.
19. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Intervention (PEPI) trial. JAMA 1996;275:370-375.
20. Pickar JH, Yeh I, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and mc-droxyprogesterone acetate. Fertil Steril 2001;76:25-31.
21. Speroff L, Rowan J, Symons J, Genant H, Wilborn W, for the CHART Study Group. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study): a randomized controlled trial. JAMA 1996;276:1397-1403.
22. Woodruff D, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994;170:1213-1223.
23. Archer DF, Furst K, Tipping D, Dain MP, Vandepol C. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol 1999;94:498-503.
24. Cushing KL, Weiss NS, Voigt LF, McKnight B, Beresford SA. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens. Obstet Gynecol 1998;91:35-39.
25. Weiderpass E, Baron JA, Adami HO, et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 1999;353:1824-1828.
26. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458-461.
27. Pike MC, Peters RK, Cozen W, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110-1116.
28. Gambrell RD Jr. Strategies to reduce the incidence of endometrial cancer in postmenopausal women. Am J Obstet Gynecol 1997;177:1196-1207.
29. Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 1989;160:126-131.
30. Lindahl B, Willen R. Spontaneous endometrial hyperplasia: a 5 year follow-up of 82 patients after high-dose gestagen treatment. Anticancer Res 1994;14:2831-2834.
31. Norman TR, Morse CA, Dennerstein L. Comparative bioavailability of orally and vaginally administered progesterone. Fertil Steril 1991;56:1034-1039.
32. Ross D, Cooper AJ, Pryse-Davies J, Bergeron C, Collins WP, Whitehead MI. Randomized, double-blind, dose-ranging study of the endometrial effects of a vaginal progesterone gel in estrogen-treated postmenopausal women. Am J Obstet Gynecol 1997;177:937-941.
33. Burry KA, Patton PE, Hermsmeyer K. Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen. Obstet Gynecol 1999;180:1504-1511.
34. Cooper A, Spencer C, Whitehead MI, Ross D, Barnard GJR, Collins WP. Systemic absorption of progesterone cream from Progest cream in postmenopausal women. Lancet 1998;351:1255-1256.
35. O'Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 1995;35(9 Suppl):18S-24S.
36. Darj E, Nilsson S, Axelsson O, Hellberg D. Clinical and endometrial effects of oestradiol and progesterone in postmenopausal women. Maturitas 1991;13:109-115.
37. de Lignieres B. Endometrial hyperplasia: risks, recognition and the search for a safe hormone replacement regimen. J Reprod Med 1999;44:191-196.
38. Archer DF, Pickar JH, Bottiglioni F, for the Menopause Study Group. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 1994;83:686-692.
39. Ettinger B, Pressman A, Van Gessel A. Low-dosage esterified estrogen opposed by progestin at 6-month intervals. Obstet Gynecol 2001;98:205-211.
40. Ettinger B, Selby J, Citron JT, et al. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 1994;83:693-700.
41. Bjarnason K, Cerin A, Lindgren R, Weber T. Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group. Maturitas 1999;32:161-170.
42. Lethaby A, Farquhar C, Sarkis A, Roberts H, Jepson R, Barlow D. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2000;2:CD000402.
43. Brynhildsen J, Hammar M. Low dose transdermal estradiol/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women. Menopause 2002;9:137-144.
44. Casper RF. Estrogen with interrupted progestin HRT: a review of experimental and clinical studies. Maturitas 2000;34:97-108.
45. Sulak PJ, Caubal R, Lane R. Efficacy and safety of a constant-estrogen, pulsed-progestin regimen in hormone replacement therapy. Int J Fertil Womens Med 1999;44:286-296.
46. Corson SL, Richart RM, Caubel P, Lim P. Effect of a unique constant-estrogen, pulsed-progestin hormone replacement therapy containing 17beta-estradiol and norgestimate on endometrial histology. Int J Fertil Womens Med 1999;44:279-285.
47. Casper RF, Chapdelaine A. Estrogen and interrupted progestin: a new concept for menopausal hormone replacement therapy. Am J Obstet Gynecol 1993;168:1188-1196.
48. Cameron ST, Critchley HOD, Glasier AF, et al. Continuous transdermal estrogen and interrupted progestogen as a novel bleed-free regimen of hormone replacement therapy for postmenopausal women. Br J Obstet Gynaecol 1997;104:1184-1190.
49. de Ziegler D, Ferriani R, Moraes LA, Bulletti C. Vaginal progesterone in menopause: Crinone 4% in cyclical and constant combined regimens. Hum Reprod 2000;15(Suppl 1):149-158.
50. Gillet JY, Andre G, Faguer B, et al. Induction of amenorrhea during hormone replacement therapy: optimal micronized progesterone dose: a multicenter study. Maturitas 1994;9:103-115.
51. Jondet M, Maroni M, Yaneva H, Brin S, Peltier-Pujol F, Pelissier C. Comparative endometrial histology in postmenopausal women with sequential hormone replacement therapy of estradiol and, either chlormadinone acetate or micronized progesterone. Maturitas 2002;41:115-121.
52. Pelissier C, Maroni M, Yaneva H, Brin S, Peltier-Pujol F, Jondet M. Chlormadinone acetate versus micronized progesterone in the sequential combined hormone replacement therapy of the menopause. Maturitas 2001;40:85-94.
53. Hill DA, Weiss NS, Beresford SA, et al. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 2000;183:1456-1461.
54. Sturdee DW, Ulrich LG, Barlow DH, et al. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. Br J Obstet Gynecol 2000;107:1392-1400.
55. Sturdee DW, Barlow DH, Ulrich LG, et al. Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestagen replacement therapy? UK Continuous Combined HRT Study Investigators [Erratum appears in Lancet. 1994;344:1516]. Lancet 1994;344:979-982.
56. Pickar JH, Archer DF. Is bleeding a predictor of endometrial hyperplasia in postmenopausal women receiving hormone replacement therapy? Menopause Study Group (United States, Italy, Netherlands, Switzerland, Belgium, Germany, and Finland). Am J Obstet Gynecol 1997;177:1178-1183.
57. Archer DF, Lobo RA, Land HF, Pickar JH. A comparative study of transvaginal uterine ultrasound and endometrial biopsy for evaluating the endometrium of postmenopausal women taking hormone replacement therapy. Menopause 1999;6:201-208.
58. Archer DF, Pickar JH, Bottiglioni F, for the Menopause Study Group. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 1994;83:686-692.
59. Udoff L, Langenberg P, Adashi EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 1995;86:306-316.
60. Wells M, Sturdee DW, Barlow DH, et al. Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study. BMJ 2002;325:239-244.
61. Shau W-Y, Hsieh C-C, Hsieh T-T, Hung T-H, Huang K-E. Factors associated with endometrial bleeding in continuous hormone replacement therapy. Menopause 2002;9:188-194.
62. Ettinger B, Li D-K, Klein R. Unexpected vaginal bleeding and associated gynecologic care in postmenopausal women using hormone therapy: comparison of cyclic versus continuous combined schedules. Fertil Steril 1998;69:865-869.
63. Ettinger B, Li D-K, Klein R. Continuation of postmenopausal hormone replacement therapy: comparison of cyclic versus continuous combined schedule. Menopause 1996;3:185-189.
64. Andersson B, Mattsson LA, Rybo G, Stradberg E. Intrauterine release of levonorgestrel; a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992;79:963-967.
65. Suvanto-Luukkonen E, Malinen H, Sundstrom H, Penttinen J, Kauppila A. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone. Acta Obstet Gynecol Scand 1998;77:758-763.
66. Shoupe D, Meme D, Mezrow G, Lobo RA. Prevention of endometrial hyperplasia in postmenopausal women with intrauterine progesterone [letter]. N Engl J Med 1991;325:1811-1812.
67. Archer DF, Viniegra-Sibal A, Hsiu J-G, Seltman HJ, Muesing R, Ross B. Endometrial history, uterine bleeding, and metabolic changes in postmenopausal women using a progesterone-releasing intrauterine device and oral conjugated estrogens for hormone replacement therapy. Menopause 1994;1:109-116.
68. Raudaskoski T, Tapanainen J, Tomás E, et al. Intrauterine 10μg and 20μg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. Br J Obstet Gynaecol 2002;109:136-144.
69. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-1811.
70. Karas RH, van Eickels M, Lydon JP, et al. A complex role for the progesterone receptor in the response to vascular injury. J Clin Invest 2001;108:611-618.
71. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-1775.
72. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-941.
73. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998;19:55-72.
74. Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study: a prospective, observational study. Ann Intern Med 2001;135:1-8.
75. The Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002;288:321-333.
76. Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-613.
77. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin replacement study follow-up (HERS II). JAMA 2002;288:49-57.
78. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-529.
79. The North American Menopause Society. Amended report from the NAMS Advisory Panel on Postmenopausal Hormone Therapy. Menopause 2003;10:6-12.
80. US Preventive Services Task Force. Postmenopausal hormone replacement therapy for the primary prevention of chronic conditions: recommendations and rationale. Available at: http://www.ahcpr.gov/clinic/3rduspstf/hrt/. Accessed October 31, 2002.
81. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis 1990;10:1051-1057.
82. Adams MR, Register TC, Golden DL, et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:217-221.
83. Clarkson TB, Anthony MS, Wagner JD. A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. J Clin Endocrinol Metab 2001;86:5396-5404.
84. Hanke H, Hanke S, Bruck B, et al. Inhibition of the protective effect of estrogen by progesterone in experimental atherosclerosis. Atherosclerosis 1996;121:129-138.
85. Hanke H, Kamenz J, Hanke S, et al. Effect of 17-β estradiol on pre-existing atherosclerotic lesions: role of the endothelium. Atherosclerosis 1999;147:123-132.
86. Holm P, Andersen HL, Andersen MR, et al. The direct antiatherogenic effect of estrogen is present, absent, or reversed, depending on the state of the arterial endothelium: a time course study in cholesterol-clamped rabbits. Circulation 1999;100:1727-1733.
87. Williams JK, Anthony MS, Honoré EK, et al. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol 1995;15:827-836.
88. Westendorp ICD, Veld I, Bots ML, et al. Hormone replacement therapy and intima-media thickness of the common carotid artery: the Rotterdam study. Stroke 1999;30:2562-2567.
89. Hodis HN, Mack WJ, Lobo RA, et al, for the Estrogen in the Prevention of Atherosclerosis Trial Research Group. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-953.
90. Angerer P, Stàrk S, Kothny W, Schmitt P, von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001;21:262-268.
91. Williams JK, Honoré EK, Washburn SA, Clarkson TB. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol 1994;24:1757-1761.
92. Williams JK, Cline JM, Honoré EK, et al. Coadministration of nomegestrol acetate does not diminish the beneficial effects of estradiol on coronary artery dilator responses in nonhuman primates (Macaca fascicularis). Am J Obstet Gynecol 1998;179:1288-1294.
93. Miyagawa K, Rosch J, Stanczyk F, et al. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 1997;3:324-327.
94. Herrington DM, Braden GA, Williams JK, et al. Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol 1994;73:951-952.
95. Reis SE, Gloth ST, Blumenthal RS, et al. Ethinyl estradiol acute attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994;89:52-60.
96. Koh KK, Jin DK, Yang SH, et al. Vascular effects of synthetic or natural progestogen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation 2001;103:1961-1966.
97. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation 2001;104:1773-1778.
98. Sorensen KE, Dorup I, Hermann AP, Mosekilde L. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation 1998;97:1234-1238.
99. Rosselli M, Imthurn B, Keller PJ, Jackson EK, Dubey RK. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17β-estradiol and norethisterone acetate: a two-year follow-up study. Hypertension 1995;25:848-853.
100. Herrington DM, Espeland MA, Crouse JR, et al. Estrogen replacement and brachial artery flow-mediated vasodilation in older women. Arterioscler Thromb Vasc Biol 2001;21:1955-1961.
101. Haines CJ, Yim SF, Sanderson JE. The effect of continuous combined hormone replacement therapy on arterial reactivity in postmenopausal women with established angina pectoris. Atherosclerosis 2001;159:467-470.
102. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 2002;9:6-15.
103. Honoré EK, Williams JK, Adams MR, Ackerman DM, Wagner JD. Methyltestosterone does not diminish the beneficial effects of estrogen replacement therapy on coronary artery reactivity in cynomolgus monkeys. Menopause 1996;3:20-26.
104. Barrett-Connor E, Wingard DL, Criqui MH. Postmenopausal estrogen use and heart disease risk factors in the 1980s: Rancho Bernardo, Calif, revisited. JAMA 1989;261:2095-2100.
105. Langer RD. Progestins: pharmacologic characteristics and clinically relevant differences. Int J Fertil 2000;45(Suppl 1):63-72.
106. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial [erratum appears in JAMA. 1995;274: 1676]. JAMA 1995;273:199-208.
107. Davidson MH, Maki KC, Marx P, et al. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med 2000;160:3315-3325.
108. Espeland MA, Marcovina SM, Miller V, et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. Circulation 1998;97:979-986.
109. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001;75:898-915.
110. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000;283:1845-1852.
111. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Circulation 1999;100:717-722.
112. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999;100:713-716.
113. Sattar N, Perera M, Small M, Lumsden MA, Hormone replacement therapy and sensitive C-reactive protein concentrations in type-2 diabetes [Letter]. Lancet 1999;354:487-488
114. Koh KK, Mincemoyer R, Bui MN, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997;336:683-690.
115. Kessler CM, Szymanski LM, Shamsipour Z, Muesing RA, Miller VT, Larosa JC. Estrogen replacement therapy and coagulation: relationship to lipid and lipoprotein changes. Obstet Gynecol 1997;89:326-331.
116. Herkert O, Kuhl H, Sandow J, Busse R, Schini-Kerth VB. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation 2001;104:2826-2831.
117. Psaty BM, Smith NL, Lemaitre RN, et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 2001;285:906-913.
118. Lindheim SR, Presser SC, Ditkoff EC, Vijod MA, Stanczyk FZ, Lobo RA. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 1993;60:664-667.
119. Wagner JD, Thomas MJ, Williams JK, Zhang L, Greaves KA, Cefalu WT. Insulin sensitivity and cardiovascular risk factors in ovariectomized monkeys with estradiol alone or combined with nomegestrol acetate. J Clin Endocrinol Metab 1998;83:896-901.
120. Cefalu WT, Wagner JD, Bell-Farrow AD, et al. The effects of hormonal replacement therapy on insulin sensitivity in surgically postmenopausal cynomolgus monkeys (Macaca fascicularis). Am J Obstet Gynecol 1994;171:440-445.
121. Godsland IF, Gangar K, Walton C, et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993;42:846-853.
122. Friday KE, Dong C, Fontenot RU. Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2001;86:48-52.
123. Manning PJ, Allum A, Jones S, Sutherland WHF, Williams SM. The effect of hormone replacement therapy on cardiovascular risk factors in type 2 diabetes: a randomized controlled trial. Arch Intern Med 2001;161:1772-1776.
124. Andersson B, Mattsson L-Å, Hahn L, et al. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997;82:638-643.
125. Tilly-Kiesi M, Kahri J, Pyorala T, et al. Responses of HDL subclasses, Lp (A-I) and Lp (A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women. Atherosclerosis 1997;129:249-259.
126. Lobo RA, Bush T, Carr BR, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 2001;76:13-24.
127. The Writing Group for the PEPI Study. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1996;276:1389-1396.
128. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002;287:2668-2676.
129. Ferguson DJP, Anderson TJ. Morphological evaluation of cell turnover in relation to menstrual cycle in the "resting" human breast. Br J Cancer 1981;44:177-181.
130. Going JJ, Anderson TJ, Battersby S, MacIntyre CC. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol 1988;130:193-204.
131. Longacre TA, Bartow SA. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 1986;10:382-393.
132. Chang K-J, Lee TTY, Linares-Cruz G, et al. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril 1995;63:785-791.
133. Laidlaw IJ, Clarke RB, Howell A, et al. The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology 1995;136:164-171.
134. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev 1997;18:502-519.
135. Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev 1990;11:266-301.
136. Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 1996;174:93-100.
137. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559-4565.
138. Kester HA, van der Leede BM, van der Saag PT, et al. Novel progesterone target genes identified by an improved differential display technique suggest that progestin-induced growth inhibition of breast cancer cells coincides with enhancement of differentiation. J Biol Chem 1997;272:16637-16643.
139. Musgrove EA, Hamilton JA, Lee CS, et al. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 1993;13:3577-3587.
140. Hurd C, Khattree N, Alban P, et al. Hormonal regulation of the p53 tumor suppressor protein in T47D human breast carcinoma cell line. J Biol Chem 1995;270:28507-28510.
141. Clarke RB, Howell A, Potten CS, et al. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997;57:4987-4991.
142. Musgrove EA, Lee CS, Sutherland RL. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 1991;11:5032-5043.
143. Hyder SM, Murthy L, Stancel GM. Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res 1998;58:392-395.
144. Catherino WH, Jeng MH, Jordan VC. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer 1993;67:945-952.
145. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) investigators. Ann Intern Med 1999;130:262-269.
146. Erel CT, Esen G, Seyisoglu H, et al. Mammographic density increase in women receiving different hormone replacement regimens. Maturitas 2001;40:151-157.
147. Sendag F, Cosan TM, Ozsener S, et al. Mammographic density changes during different postmenopausal hormone replacement therapies. Fertil Steril 2001;76:445-450.
148. Warner E, Lockwood G, Trechler D, Boyd NF. The risk of breast cancer associated with mammographic parenchymal patterns: a meta-analysis of the published literature to examine the effect of method of classification. Cancer Detect Prev 1992;16:67-72.
149. Lippert C, Seeger H, Wallwiener D, Mueck AO. Comparison of the effects of continuous combined and sequential combined medroxyprogesterone acetate-estradiol treatment on the proliferation of MCF-7 cells. Climacteric 2000;3:271-277.
150. Plu-Bureau G, Le MG, Sitruk-Ware R, Thalabard JC, Mauvais-Jarvis P. Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease. Br J Cancer 1994;70:270-277.
151. Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulates the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963-969.
152. Newcomb PA, Longnecker MP, Storer BE, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women [erratum appears in Am J Epidemiol. 1996;143:52]. Am J Epidemiol 1995;142:788-795.
153. Chen C-L, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA 2002;287:734-741.
154. Li CL. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 2000;88:2570-2577.
155. Magnusson C, Baron JA, Correira N, et al. Breast cancer risk following long term oestrogen and oestrogen-progestin replacement therapy. Int J Cancer 1999;31:339-344.
156. Ross RK, Paganini-Hill A, Wan PC, et al. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-332.
157. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-491.
158. Weiss LK, Burkman RT, Cushing-Haugen KL, et al. Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol 2002;100:1148-1158.
159. Utian WH, Shoupe D, Bachmann G, et al. Relief of vasomotor symptoms and vaginal atrophy with lower dose of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065-1079.
160. Sherwin BB. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab 1991;72:336-343.
161. de Lignieres B, Vincens M. Differential effects of exogenous oestradiol and progesterone on mood in postmenopausal women: individual dose/effect relationship. Maturitas 1982;4:67-72.
162. Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000;183:414-420.
163. El-Etr M, Schumacher M, Baulieu EE. Effects of progesterone and related steroids in the brain. In: Sitruk-Ware M, Mishell D, eds. Progestins and Antiprogestins in Clinical Practice. New York, NY: Marcel Dekker, 2000:15-58.
164. Gyerneck L, Soyka LF. Steroid anesthetics. Anesthesiology 1975;42:331-334.
165. Paul SM, Purdy RH. Neuroactive steroids. FASEBJ 1992;6:2311-2322.
166. de Lignieres B, Dennerstein L, Backstrom T. Influence of route of administration on progesterone metabolism. Maturitas 1995;21:251-257.
167. de Wit H, Schmitt L, Purdy R, Hauger R. Effects of acute progesterone administration in healthy postmenopausal women and normally-cycling women. Psychoneuroendocrinology 2001;26:697-710.
168. Freeman EW, Purdy RH, Coutifaris C, Rickels K, Paul SM. Anxiolytic metabolites of progesterone: correlation with mood and performance measures following oral progesterone administration to healthy female volunteers. Neuroendocrinology 1993;58:478-484.
169. Björn I, Bixo M, Nojd KS, Nyberg S, Backström T. Negative mood changes during hormone replacement therapy: a comparison of two progestogens. Am J Obstet Gynecol 2000;183:1419-1426.
170. Ödmark IS, Jonsson B, Bäckström T. Bleeding patterns in postmenopausal women using continuous combination hormone replacement therapy with conjugated estrogen and medroxyprogesterone acetate of with 17β-estradiol and norethindrone acetate. Am J Obstet Gynecol 2001;184:1131-1138.
171. Goldstein SR. Endometrial safety during hormone replacement therapy: comparison of transvaginal sonography and endometrial biopsy. Menopause 1998;5:132-133.
172. Langer RD, Pierce JJ, O'Hanlan KA, et al, for the Postmenopausal Estrogen/Progestin Interventions trial. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. N Engl J Med 1997;337:1792-1798.
173. Prior JC, Alojado N, McKay DW, Vigna YM. No adverse effects of medroxyprogesterone treatment without estrogen in postmenopausal women: double-blind, placebo-controlled, crossover trial. Obstet Gynecol 1994;83:24-28.